Association of expression of mitotic spindle positioning protein with clinicopathologic features and postoperative prognosis in non-small cell lung cancer patients: a single-center retrospective study

This study analyzed the relationship between expression of mitotic spindle positioning (MISP) protein and clinicopathologic features and postoperative prognosis of non-small cell lung cancer (NSCLC) patients. A total of 306 NSCLC patients were retrospectively enrolled. MISP expression in tumor tissues was assessed via the GEPIA2 database and validated by immunohistochemistry in tumor and adjacent normal tissues. Patients were divided into low- (MISP L ) and high-expression (MISP H ) groups. Kaplan-Meier curves and Cox regression models were used to assess prognosis and identify risk factors for 5-year outcomes. Subgroup analyses were stratified by histological type. MISP was upregulated in tumor tissues. Elevated MISP expression was observed in patients with stage IIIA, lymph node metastasis, and EGFR mutations, while lower expression was noted in those receiving adjuvant chemotherapy. The MISP H group exhibited significantly shorter disease-free survival and overall survival. High MISP expression and lymph node metastasis were independent risk factors for recurrence. In the entire cohort, high MISP expression was also an independent risk factor for death ( P = 0.009). In lung adenocarcinoma, high MISP expression was an independent risk factor for 5-year postoperative disease recurrence ( HR = 4.095); in lung squamous cell carcinoma, it was associated with shorter overall survival ( P = 0.014). MISP expression is associated with tumor node metastasis stage, lymph node metastasis, and EGFR mutation in NSCLC patients. Diseasefree survival and overall survival are significantly shorter in NSCLC patients with high MISP.